How much revenue did RemeGen Co generate this year?
RemeGen Co has achieved a revenue of 1.67 B CNY this year.
RemeGen Co Revenue 2024
RemeGen Co Revenue
1.67 B CNY
Ticker
9995.HK
ISIN
CNE1000048G6
WKN
A2QGM4
In 2024, RemeGen Co's sales reached 1.67 B CNY, a 54.48% difference from the 1.08 B CNY sales recorded in the previous year.
The RemeGen Co Revenue history
| YEAR | REVENUE (undefined CNY) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 6.76 | 12,21 |
| 2028e | 5.69 | 14,50 |
| 2027e | 4.23 | 19,54 |
| 2026e | 3.14 | 26,26 |
| 2025e | 2.3 | 35,85 |
| 2024e | 1.67 | 49,35 |
| 2023 | 1.08 | 76,24 |
| 2022 | 0.77 | 64,77 |
| 2021 | 1.42 | 95,28 |
| 2020 | - | - |
| 2019 | - | - |
| 2018 | 0.01 | 21,24 |
RemeGen Co Revenue, EBIT, Net Income CNE1000048G6 · A2QGM4
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into RemeGen Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by RemeGen Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects RemeGen Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of RemeGen Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into RemeGen Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing RemeGen Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on RemeGen Co’s growth potential.
RemeGen Co Revenue, EBIT and net profit per share
| Date | RemeGen Co Revenue | RemeGen Co EBIT | RemeGen Co Net Income |
|---|---|---|---|
| 2029e | 6.76 B undefined | 2.53 B undefined | 0 undefined |
| 2028e | 5.69 B undefined | 1.79 B undefined | 0 undefined |
| 2027e | 4.23 B undefined | 424.89 M undefined | 0 undefined |
| 2026e | 3.14 B undefined | -188.67 M undefined | -178.9 M undefined |
| 2025e | 2.3 B undefined | -899.06 M undefined | -831.68 M undefined |
| 2024e | 1.67 B undefined | -1.52 B undefined | -1.44 B undefined |
| 2023 | 1.08 B undefined | -1.52 B undefined | -1.51 B undefined |
| 2022 | 772.11 M undefined | -1.08 B undefined | -998.83 M undefined |
| 2021 | 1.42 B undefined | 238.8 M undefined | 276.3 M undefined |
| 2020 | 0 undefined | -670.2 M undefined | -697.8 M undefined |
| 2019 | 0 undefined | -386.4 M undefined | -430.3 M undefined |
| 2018 | 11.3 M undefined | -231.4 M undefined | -269.9 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2018 | 11.3 M CNY | -231.4 M CNY | -269.9 M CNY |
| 2019 | 0 CNY | -386.4 M CNY | -430.3 M CNY |
| 2020 | 0 CNY | -670.2 M CNY | -697.8 M CNY |
| 2021 | 1.42 B CNY | 238.8 M CNY | 276.3 M CNY |
| 2022 | 772.11 M CNY | -1.08 B CNY | -998.83 M CNY |
| 2023 | 1.08 B CNY | -1.52 B CNY | -1.51 B CNY |
| 2024e | 1.67 B CNY | -1.52 B CNY | -1.44 B CNY |
| 2025e | 2.3 B CNY | -899.06 M CNY | -831.68 M CNY |
| 2026e | 3.14 B CNY | -188.67 M CNY | -178.9 M CNY |
| 2027e | 4.23 B CNY | 424.89 M CNY | 0 CNY |
| 2028e | 5.69 B CNY | 1.79 B CNY | 0 CNY |
| 2029e | 6.76 B CNY | 2.53 B CNY | 0 CNY |
RemeGen Co stock margins CNE1000048G6 · A2QGM4
The RemeGen Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of RemeGen Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for RemeGen Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the RemeGen Co's sales revenue. A higher gross margin percentage indicates that the RemeGen Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the RemeGen Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the RemeGen Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the RemeGen Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the RemeGen Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the RemeGen Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
RemeGen Co Margin History
| RemeGen Co Gross margin | RemeGen Co Profit margin | RemeGen Co EBIT margin | RemeGen Co Profit margin |
|---|---|---|---|
| 2029e | 76.24 % | 37.44 % | 0 % |
| 2028e | 76.24 % | 31.47 % | 0 % |
| 2027e | 76.24 % | 10.05 % | 0 % |
| 2026e | 76.24 % | -6 % | -5.69 % |
| 2025e | 76.24 % | -39.04 % | -36.11 % |
| 2024e | 76.24 % | -91.02 % | -86.09 % |
| 2023 | 76.24 % | -139.9 % | -139.55 % |
| 2022 | 64.77 % | -139.28 % | -129.36 % |
| 2021 | 95.28 % | 16.77 % | 19.4 % |
| 2020 | 76.24 % | 0 % | 0 % |
| 2019 | 76.24 % | 0 % | 0 % |
| 2018 | 21.24 % | -2,047.79 % | -2,388.5 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2018 | 21.24 % | -2,047.79 % | -2,388.5 % |
| 2019 | 76.24 % | 0 % | 0 % |
| 2020 | 76.24 % | 0 % | 0 % |
| 2021 | 95.28 % | 16.77 % | 19.4 % |
| 2022 | 64.77 % | -139.28 % | -129.36 % |
| 2023 | 76.24 % | -139.9 % | -139.55 % |
| 2024e | 76.24 % | -91.02 % | -86.09 % |
| 2025e | 76.24 % | -39.04 % | -36.11 % |
| 2026e | 76.24 % | -6 % | -5.69 % |
| 2027e | 76.24 % | 10.05 % | 0 % |
| 2028e | 76.24 % | 31.47 % | 0 % |
| 2029e | 76.24 % | 37.44 % | 0 % |
RemeGen Co Aktienanalyse
What does RemeGen Co do?
RemeGen Co Ltd is a Chinese biotechnology company based in Yantai. The company was founded in 2008 by Dr. Li Zhu, who also developed the company's main product. RemeGen's goal is to develop innovative therapies for the treatment of cancer and autoimmune diseases. The company's business model involves researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. RemeGen works closely with leading researchers from around the world and conducts clinical trials to assess the safety and efficacy of its products. The company has various divisions focused on developing drugs for different diseases, including oncology, autoimmune diseases, and dermatology. RemeGen's flagship product is the antibody FGFR4, which is a new therapeutic agent for treating liver cancer. FGFR4 is one of the most highly expressed genes in liver cancer cells and plays a crucial role in tumor progression. The antibody inhibits the activity of FGFR4, thereby preventing the growth of liver cancer cells. Clinical studies have shown FGFR4 to be a promising treatment option for liver cancer, with positive results. In addition to FGFR4, RemeGen has other promising products in its development pipeline, including the antibody RC48, which is used in the treatment of advanced or metastatic lung cancer. RC48 targets the Epidermal Growth Factor Receptor (EGFR), a protein that is highly upregulated in many types of cancer and promotes the growth of cancer cells. Clinical studies have shown RC48 to be a promising treatment option for lung cancer, reaching Phase III. Overall, RemeGen Co Ltd has a promising approach to developing innovative drugs that have the potential to change the standard of care in oncology, autoimmune diseases, and dermatology. Through close collaboration with leading researchers and clinical trials, the company is well-positioned to further develop its pipeline and improve medical care for patients in China and worldwide. Answer: RemeGen Co Ltd is a Chinese biotechnology company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. It has a business model of researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. The company's divisions focus on oncology, autoimmune diseases, and dermatology. Its flagship product is the antibody FGFR4, which is used for treating liver cancer. RemeGen also has other promising products, such as the antibody RC48 for advanced lung cancer. The company's approach has the potential to change the standard of care in these medical fields. RemeGen Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding RemeGen Co's Sales Figures
The sales figures of RemeGen Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing RemeGen Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize RemeGen Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in RemeGen Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about RemeGen Co stock
How much was the turnover of the company RemeGen Co compared to the previous year?
The revenue of RemeGen Co has increased by 54.48% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of RemeGen Co?
The revenue of RemeGen Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of RemeGen Co measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of RemeGen Co so important for investors?
The revenue of RemeGen Co is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does RemeGen Co pay?
Over the past 12 months, RemeGen Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RemeGen Co is expected to pay a dividend of 0 CNY.
What is the dividend yield of RemeGen Co?
The current dividend yield of RemeGen Co is .
When does RemeGen Co pay dividends?
RemeGen Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of RemeGen Co?
RemeGen Co paid dividends every year for the past 0 years.
What is the dividend of RemeGen Co?
For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.
In which sector is RemeGen Co located?
RemeGen Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von RemeGen Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of RemeGen Co from 12/16/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 12/16/2024.
When did RemeGen Co pay the last dividend?
The last dividend was paid out on 12/16/2024.
What was the dividend of RemeGen Co in the year 2023?
In the year 2023, RemeGen Co distributed 0 CNY as dividends.
In which currency does RemeGen Co pay out the dividend?
The dividends of RemeGen Co are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von RemeGen Co
Our stock analysis for RemeGen Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RemeGen Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
